Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Delayed Quote USD

ProPhase Labs, Inc. (PRPH)

Compare
0.4400
-0.0200
(-4.35%)
At close: March 28 at 4:00:00 PM EDT
0.4274
-0.01
(-2.86%)
Pre-Market: 6:32:17 AM EDT
Loading Chart for PRPH
  • Previous Close 0.4600
  • Open 0.4654
  • Bid --
  • Ask --
  • Day's Range 0.3782 - 0.5075
  • 52 Week Range 0.2200 - 7.4800
  • Volume 3,288,454
  • Avg. Volume 10,165,535
  • Market Cap (intraday) 13.3M
  • Beta (5Y Monthly) -0.51
  • PE Ratio (TTM) --
  • EPS (TTM) -1.5300
  • Earnings Date Mar 31, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 24, 2022
  • 1y Target Est 13.80

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

www.prophaselabs.com

113

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRPH

View More

Performance Overview: PRPH

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRPH
42.11%
S&P 500 (^GSPC)
5.11%

1-Year Return

PRPH
93.20%
S&P 500 (^GSPC)
6.22%

3-Year Return

PRPH
93.80%
S&P 500 (^GSPC)
21.97%

5-Year Return

PRPH
71.83%
S&P 500 (^GSPC)
119.59%

Compare To: PRPH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRPH

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    13.30M

  • Enterprise Value

    42.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.64

  • Price/Book (mrq)

    0.35

  • Enterprise Value/Revenue

    3.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -217.64%

  • Return on Assets (ttm)

    -24.12%

  • Return on Equity (ttm)

    -58.71%

  • Revenue (ttm)

    12.75M

  • Net Income Avi to Common (ttm)

    -27.76M

  • Diluted EPS (ttm)

    -1.5300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    503k

  • Total Debt/Equity (mrq)

    77.62%

  • Levered Free Cash Flow (ttm)

    -288k

Research Analysis: PRPH

View More

Company Insights: PRPH

Research Reports: PRPH

View More

People Also Watch